ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.04%
US Dollar vs MXN
18.1108
0.00%
Brent Oil
84.39
0.00%
Bitcoin
64,455.75
0.33%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lumos Pharma Inc (LUMO)

  7. Lumos Pharma Inc (LUMO) Noticias

LUMO

Lumos Pharma (LUMO)

Lumos Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LUMO
FechaHoraFuenteTítuloSímboloCompañía
07/06/202415:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/06/202415:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LUMOLumos Pharma Inc
04/06/202408:00GlobeNewswire Inc.Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024NASDAQ:LUMOLumos Pharma Inc
20/05/202415:05GlobeNewswire Inc.Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024NASDAQ:LUMOLumos Pharma Inc
14/05/202415:15GlobeNewswire Inc.Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsNASDAQ:LUMOLumos Pharma Inc
09/05/202413:51GlobeNewswire Inc.Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024NASDAQ:LUMOLumos Pharma Inc
18/04/202415:05GlobeNewswire Inc.Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsNASDAQ:LUMOLumos Pharma Inc
20/03/202407:00GlobeNewswire Inc.Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042NASDAQ:LUMOLumos Pharma Inc
07/03/202415:48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LUMOLumos Pharma Inc
07/03/202415:01GlobeNewswire Inc.Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateNASDAQ:LUMOLumos Pharma Inc
26/02/202408:00GlobeNewswire Inc.Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024NASDAQ:LUMOLumos Pharma Inc
06/02/202415:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202415:05GlobeNewswire Inc.Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceNASDAQ:LUMOLumos Pharma Inc
10/01/202418:03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
04/01/202415:05GlobeNewswire Inc.Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerNASDAQ:LUMOLumos Pharma Inc
29/11/202315:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LUMOLumos Pharma Inc
21/11/202315:15GlobeNewswire Inc.Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone DeficiencyNASDAQ:LUMOLumos Pharma Inc
20/11/202315:05GlobeNewswire Inc.Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in NovemberNASDAQ:LUMOLumos Pharma Inc
07/11/202317:24Dow Jones NewsLumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All EndpointsNASDAQ:LUMOLumos Pharma Inc
07/11/202316:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LUMOLumos Pharma Inc
07/11/202315:35GlobeNewswire Inc.Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development UpdatesNASDAQ:LUMOLumos Pharma Inc
07/11/202315:01GlobeNewswire Inc.Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary EndpointsNASDAQ:LUMOLumos Pharma Inc
26/09/202308:00GlobeNewswire Inc.Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual MeetingNASDAQ:LUMOLumos Pharma Inc
14/09/202307:00GlobeNewswire Inc.Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual MeetingNASDAQ:LUMOLumos Pharma Inc
07/09/202315:34GlobeNewswire Inc.Lumos Pharma Announces Participation in Investor Conferences in SeptemberNASDAQ:LUMOLumos Pharma Inc
22/08/202308:00GlobeNewswire Inc.Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic LandscapeNASDAQ:LUMOLumos Pharma Inc
09/08/202315:01GlobeNewswire Inc.Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical UpdateNASDAQ:LUMOLumos Pharma Inc
26/07/202308:00GlobeNewswire Inc.Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023NASDAQ:LUMOLumos Pharma Inc
12/07/202307:00GlobeNewswire Inc.Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences SummitNASDAQ:LUMOLumos Pharma Inc
28/06/202315:01GlobeNewswire Inc.Lumos Pharma Announces Departure of Chief Medical OfficerNASDAQ:LUMOLumos Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LUMO

Su Consulta Reciente

LSE
0MUO
Prefab
POLO
DEDEUSDT
Dede
BIT
P1QTO8
BNP Paribas Issuance
NASDAQ
ODVWZ
Osisko Development
EU
9643T
9643T
USOTC
SNLAF
Sino Land (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados